Literature DB >> 13417097

A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671.

J J BURNS, T F YU, A RITTERBAND, J M PEREL, A B GUTMAN, B B BRODIE.   

Abstract

Entities:  

Keywords:  ANALGESICS/effects; URIC ACID/in urine

Mesh：

Substances：

Year:  1957        PMID： 13417097

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN： 0022-3565            Impact factor:   4.030


× No keyword cloud information.
  30 in total

1.  Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.

Authors:  T F YU; A B GUTMAN
Journal:  J Clin Invest       Date:  1959-08       Impact factor: 14.808

2.  MUTUAL SUPPRESSION OF THE URICOSURIC EFFECTS OF SULFINPYRAZONE AND SALICYLATE: A STUDY IN INTERACTIONS BETWEEN DRUGS.

Authors:  T F YUE; P G DAYTON; A B GUTMAN
Journal:  J Clin Invest       Date:  1963-08       Impact factor: 14.808

3.  Tubular secretion of urate in man.

Authors:  A B GUTMAN; T F YU; L BERGER
Journal:  J Clin Invest       Date:  1959-10       Impact factor: 14.808

4.  Sulphinpyrazone in the treatment of arthritis associated with hyperuricaemia.

Authors:  E N GLICK
Journal:  Proc R Soc Med       Date:  1961-05

5.  Value of uricosuric agents and in particular of G. 28 315 in gout.

Authors:  G D KERSLEY; E R COOK; D C TOVEY
Journal:  Ann Rheum Dis       Date:  1958-09       Impact factor: 19.103

6.  Renal regulation of uric acid excretion in normal and gouty man; modification by uricosuric agents.

Authors:  A B GUTMAN; T F YU
Journal:  Bull N Y Acad Med       Date:  1958-05

7.  Evaluation of uricosuric agents in chronic gout.

Authors:  M A OGRYZLO; J HARRISON
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

8.  Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years.

Authors:  E Walter; C Staiger; J de Vries; E Weber; W Bitzer; M Degott; K Jüngling
Journal:  Klin Wochenschr       Date:  1982-11-15

9.  Induction of drug metabolizing enzymes by sulfinpyrazone.

Authors:  E Walter; C Staiger; J de Vries; R Zimmermann; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.

Authors:  H A Strong; R Angus; J Oates; J Sembi; P Howarth; A G Renwick; C F George
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.